


FORM PTO-1449 (REV. 7-08)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF PRIOR ART CITED BY APPLICANT <small>(Use several sheets if necessary)</small> <small>NOV 08 2004</small> <small>SEARCH & TRADEMARKS U.S.A.</small>				ATTY. DOCKET NO.: 200.1079CON4		SERIAL NO.: 10/056,348	
				APPLICANT(S): Ronald BURCH et al.			
				FILING DATE: January 25, 2002		GROUP: 1639	
U.S. PATENT DOCUMENTS							
*EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AD						Yes No
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AE	Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; July 28, 2003					
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
	AO						
	AP						
	AQ						
	AR						
	AS						
EXAMINER				DATE CONSIDERED <i>11/7/05</i>			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO.: 200.1079CON4		SERIAL NO.: 10/056,348		
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)					APPLICANT(S): Ronald BURCH et al.				
					FILING DATE: January 25, 2002		GROUP: 1639		
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA								
	AB								
	AC								
	AD								
	AE								
	AF								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AG								Yes No
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
	AH	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," Arzneim-Forsch./Drug res. 42 (II), Nr. 7, pp. 935-944 (1992)							
	AI	Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-steroidal Anti-inflammatory Agent with Favorable Gastrointestinal Tolerance," Inflamm. Res. 44:423-433 (1995)							
	AJ	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," Brit. J. Rheumatology 1996;35 (suppl. 1): 4-12							
	AK	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," Brit. J. Rheumatology 1996;35 (suppl. 1):68-77							
	AL	Wojtulewski et al., " a Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," Brit. J. Rheumatology 1996;35 (suppl. 1):22-28							
	AM	Swingle et al., "Preclinical Pharmacological Studies With Nimesulide," Drugs Exptl. Clin. Res. Vol. X (8-9) pp. 587-597							
	AN	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflammatory Drug," Drugs of Today Vol 32, No.5 (1996), p9. 365-384							
	AO	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," PNAS USA Vol.91 (Dec. 1994) pages 12013-12-17							
	AP	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," Drug Safety Vol. 15(4), pp. 249-260 (Oct. 1996)							
	AQ								
EXAMINER	<i>Becker</i>				DATE CONSIDERED				<i>1/7/05</i>

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.